Cardlytics, Inc. (CDLX) — SEC Filings

Cardlytics, Inc. (CDLX) — 35 SEC filings. Latest: 8-K (Mar 24, 2026). Includes 17 8-K, 5 10-Q, 5 SC 13G/A.

View Cardlytics, Inc. on SEC EDGAR

Overview

Cardlytics, Inc. (CDLX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 24, 2026: Cardlytics, Inc. filed an 8-K on March 24, 2026, announcing the completion of an acquisition or disposition of assets under Item 2.01. While the specific details of the transaction, such as the acquired company or asset and the financial terms, are not explicitly stated in this summary, the filing i

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Cardlytics, Inc. is neutral.

Filing Type Overview

Cardlytics, Inc. (CDLX) has filed 17 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 1 8-K/A, 3 SC 13D/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (35)

Cardlytics, Inc. SEC Filing History
DateFormDescriptionRisk
Mar 24, 20268-KCardlytics Completes Asset Acquisition/Disposition on March 24, 2026
Dec 18, 20258-K8-K Filing
Dec 5, 20258-KCardlytics Reports Director/Officer Changesmedium
Nov 5, 20258-KCardlytics, Inc. Files 8-K on Financialslow
Oct 2, 20258-KCardlytics Files 8-K on Exit/Disposal Costsmedium
Aug 6, 202510-QCardlytics' Losses Widen Amidst Equity Declinehigh
Jul 8, 20258-KCardlytics Enters Material Definitive Agreementmedium
Jun 25, 20258-KCardlytics Announces Board and Executive Changesmedium
May 20, 20258-KCardlytics Director Departs; Board Changes Announcedmedium
May 7, 202510-QCardlytics Q1 2025 10-Q Filedlow
Apr 28, 20258-KCardlytics Reports Termination of Material Agreementmedium
Apr 3, 2025DEF 14ACardlytics Files DEF 14A for 2024 Executive Disclosureslow
Mar 12, 202510-KCardlytics Files 2024 10-Kmedium
Nov 12, 2024SC 13G/ASC 13G/A Filing
Nov 6, 202410-QCardlytics Q3 2024 10-Q Filedmedium
Nov 4, 20248-KCardlytics CEO Transition & Board Changesmedium
Oct 24, 2024SC 13G/ASC 13G/A Filing
Oct 3, 20248-KCardlytics, Inc. Files Material Definitive Agreementmedium
Aug 21, 20248-K/ACardlytics Files 8-K/A Amendment on Officer/Director Changeslow
Aug 7, 202410-QCardlytics Files Q2 2024 10-Qmedium

Risk Profile

Risk Assessment: Of CDLX's 25 recent filings, 1 were flagged as high-risk, 18 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Cardlytics, Inc. Financial Summary (10-Q, Aug 6, 2025)
MetricValue
Net Income-$17.5M

Key Executives

  • Jonathan L. Sokoloff
  • David L. K. Lee
  • David M. Z. Lee
  • Amit Gupta
  • Karim Temsamani
  • Lynne Laube
  • K. Brent Turner
  • Clifford Sosin
  • William J. Nowell
  • David A. DeSimone

Industry Context

Cardlytics operates within the digital advertising technology sector, a highly competitive and rapidly evolving market. The industry is characterized by a constant need for innovation to capture consumer attention and demonstrate measurable return on investment to advertisers. Key trends include the shift towards personalized advertising, the increasing importance of data privacy, and the consolidation of market players.

Top Tags

material-agreement (4) · 10-Q (4) · financials (4) · corporate-governance (3) · sec-filing (3) · 13d-amendment (3) · Cardlytics (3) · 8-K (2) · leadership-change (2) · officer-appointment (2)

Executive Compensation

From the most recent DEF 14A filing (Apr 12, 2024):

  • Karim Temsamani — Member
  • Lynne Laube — Member

Key Numbers

Cardlytics, Inc. Key Metrics
MetricValueContext
I.R.S. Employer Identification No.26-3039436Company identification number
Net Loss (Q2 2025)$17.5MIncreased from $10.2M in Q2 2024, indicating worsening profitability.
Net Loss (YTD 2025)$31.2MWidened from $20.4M in YTD 2024, showing a sustained negative trend.
Stockholders' Equity (June 30, 2025)$178.6MDecreased from $209.8M at Dec 31, 2024, reflecting erosion of shareholder value.
Accumulated Deficit (June 30, 2025)$795.5MIncreased from $764.3M at Dec 31, 2024, highlighting persistent unprofitability.
Common Shares Outstanding (June 30, 2025)39.26MSlight increase from 38.98M at Dec 31, 2024, potentially due to share-based compensation.
Reporting Period2025 Q1First quarter of 2025 financial data
As of Date2025-03-31End of the reporting period for balance sheet items
Fiscal Year End2024-12-31Reporting period for executive compensation and governance
Filing Date20250403Date the DEF 14A was submitted to the SEC
Fiscal Year2024Reporting period for the 10-K
Prior Year End2023-12-31Comparison point for financial data.
SEC File Number001-38386Identifies the company's filings with the SEC.
IRS Employer Identification No.26-3039436Company's tax identification number.
Period End Date2024-03-31Quarterly report period

Related Companies

CLI

Frequently Asked Questions

What are the latest SEC filings for Cardlytics, Inc. (CDLX)?

Cardlytics, Inc. has 35 recent SEC filings from Jan 2024 to Mar 2026, including 17 8-K, 5 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CDLX filings?

Across 35 filings, the sentiment breakdown is: 1 bearish, 33 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Cardlytics, Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cardlytics, Inc. (CDLX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cardlytics, Inc.?

Key financial highlights from Cardlytics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CDLX?

The investment thesis for CDLX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cardlytics, Inc.?

Key executives identified across Cardlytics, Inc.'s filings include Jonathan L. Sokoloff, David L. K. Lee, David M. Z. Lee, Amit Gupta, Karim Temsamani and 5 others.

What are the main risk factors for Cardlytics, Inc. stock?

Of CDLX's 25 assessed filings, 1 were flagged high-risk, 18 medium-risk, and 6 low-risk.

What are recent predictions and forward guidance from Cardlytics, Inc.?

Forward guidance and predictions for Cardlytics, Inc. are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.